CGON Multiplikator forward rega marang pendapatan CG Oncology Therapeutics

Logo perusahaan publik CG Oncology, Inc. (CGON)

CG Oncology, Inc. (CGON) is scaling the expansion of its bladder cancer viral therapy in the US. The forward P/S indicator on GURU.Markets reflects this trend, where the value of 1225.50 expresses the metric level. The diversification of mono- and combination therapy programs reduces regulatory risks, yet the absence of stable cash flows leaves the company dependent on external financing until commercial launch.

CGON CG Oncology: Rasio kapitalisasi pasar marang pendapatan mangsa ngarep ing interval 14.11.2024 - 17.11.2026

Ringkesan rincian data analitis cgoncology.com (CGON)

- rega saiki lan proyeksi nilai saham:
Analisis wiwitan perusahaan:CGON (CG Oncology Corp)
Sampel barang CG Oncology, Inc.

To objectively assess asset quality, use the ratio of current market capitalization to projected revenue, which measures the market value of each unit of future sales. By analyzing the forward price-to-sales valuation, an investor can determine if an asset is overbought, which is critical for CG Oncology, Inc. (CGON), as its commercial sector transitions into a stage of stable profit generation driven by high demand for innovative cancer therapy.

Karo sapa CG Oncology, Inc. saingan

Multiplikator Forward P/S ONC (BeiGene Oncology)|Multiplikator Forward P/S Halozyme Corp HALO|RVMD: Multiplikator forward rega marang pendapatan|Ascentage Pharma Group (AAPG) - Multiplikator forward rega marang pendapatan|URGN: Multiplikator Forward P/S|Bicara Therapeutics Inc (BCAX) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan personalis.com|Multiplikator forward rega marang pendapatan Erasca Corp (ERAS)|Multiplikator forward rega marang pendapatan DCTH (Delcath)|Rasio kapitalisasi marang dodolan sing dikarepake Y-mAbs Therapeutics, Inc.|Multiplikator Forward P/S AURA (Aura Biosciences Inc)|Rega forward marang dodolan CADL|ARAY: Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake sellaslifesciences.com SLS|ACTU (Actuate Therapeutics, Inc) - Multiplikator forward rega marang pendapatan|Kapitalisasi marang prakiraan pendapatan CTOR|Rasio rega marang prakiraan pendapatan TuHURA Biosciences Inc.|TARA: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Fate Therapeutics (FATE)|Rasio kapitalisasi marang dodolan sing dikarepake Aadi Bioscience|Rasio rega marang prakiraan pendapatan TScan Therapeutics Inc TCRX|CSBR: Kapitalisasi marang prakiraan pendapatan|XBIT: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan CVM (cel-sci.com)|OSTX: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Radiopharm Theranostics Ltd (RADX)|ARTV (Artiva) - Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan ANL (Adlai Nortye)|Rasio rega marang prakiraan pendapatan Veru Pharma (VERU)|Multiplikator Forward P/S Tempest Tx (TPST)|Rasio rega marang prakiraan pendapatan xiliotx.com XLO|Enochian BioSciences - Rasio rega marang prakiraan pendapatan|Mural Oncology - Multiplikator Forward P/S|KAPA - Multiplikator Forward P/S|OnKure Therapeutics Inc (OKUR) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan CytoMed|Rasio rega marang prakiraan pendapatan curis.com|Multiplikator forward rega marang pendapatan Apollomics, Inc. (APLM)|Multiplikator Forward P/S THAR|Advanced Biomed Corp - Kapitalisasi marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Genprex GNPX|Rasio kapitalisasi marang dodolan sing dikarepake Calidi Bio (CLDI)|sunshinebiopharma.com - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep xeneticbio.com|salariuspharma.com (SLRX) - Rasio rega marang prakiraan pendapatan|Purple Biotech Ltd. - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan AON|Multiplikator Forward P/S BeiGene Ltd.|Rasio rega marang prakiraan pendapatan Checkpoint Therapeutics, Inc. (CKPT)|Multiplikator forward rega marang pendapatan Elevation Oncology, Inc. ELEV|Multiplikator Forward P/S ICAD (iCAD Inc.)|IKNA - Multiplikator forward rega marang pendapatan|NTBL: Multiplikator forward rega marang pendapatan|viracta.com (VIRX) - Multiplikator forward rega marang pendapatan|MorphoSys (MOR) - Rasio rega marang prakiraan pendapatan|NAYA Biosciences Corp (NAYA) - Multiplikator Forward P/S|AAPGV (Ascentage) - Multiplikator Forward P/S